Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,068
datasets available to search
ShareScore release 0.9.0
Dataset results
1,068 results for “PD-1”
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
ClinicalTrials.gov study NCT03787095. IPD Sharing: YES. Countries: 1. Publications: 2.
Genomic, clinical data, and scripts for PD-1 blockade resistance in metastatic melanoma
Open the record for dataset details and reuse information.
Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase
<p>This dataset has been used to analyze the association between tumor mutational burden and response to treatment in immunotherapy-treated patients with microsatellite-stable solid tumors. The dataset contains clinical and genomic data for 1,678 patients with 16 cancer types.</p> <p> </p>
Impact of CD4 T cells on intratumoral CD8 T cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
<p>scRNA-seq data (Cellranger filtered feature-barcode matrices) and scVDJ-seq data (Cellranger filtered_contig_annotations.csv files) for publication listed above.</p>
Distinct mechanisms of mismatch repair deficiency delineate two modes of response to PD-1 immunotherapy in endometrial carcinoma
<p>Responses to immune checkpoint blockade (ICB) are variable even among mismatch repair deficient (MMRd) cancers. We completed a phase 2 clinical trial of the PD-1 inhibitor pembrolizumab in 24 patients with MMRd endometrial cancer (NCT02899793). Patients with mutational MMRd tumors (6 patients) had higher response rates and longer survival than those with epigenetic MMRd tumors (18 patients). Mutation burden was higher in tumors with mutational MMRd compared to epigenetic MMRd; however, within each category of MMRd, mutation burden was not associated with ICB response. Notably, JAK1 mutations did not confer resistance to pembrolizumab. Longitudinal single-cell RNA-seq of circulating immune cells revealed contrasting modes of anti-tumor immunity against mutational and epigenetic MMRd tumors. Whereas effector CD8+ T cell responses correlated with mutational MMRd, highly active CD16+ NK cells were associated with epigenetic MMRd tumors responsive to ICB. These data highlight factors beyond neoantigen burden that influence ICB response.</p>
Spatial dynamics of CD39⁺CD8⁺ exhausted T cells reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer
<p><strong>Data related to the paper</strong>: <em>"Spatial dynamics of CD39+CD8+ exhausted T cells reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer,”</em> <em>Nature Communications</em> (2024)</p> <p>The repository data consists of two main folders: <strong>IMC_dataset</strong> and <strong>MC_normalized_dataset</strong>.</p> <p><strong>IMC_dataset</strong> includes:</p> <ol> <li> <p><strong>IMC_denoised_dataset</strong>: This folder contains cell mask images and noise-reduced images for each sample.</p> </li> <li> <p><strong>IMC_raw_dataset</strong>: This folder contains raw, unprocessed data.</p> </li> <li> <p><strong>IMC_processed_data</strong>: This folder contains standardized single-cell information and spillover-corrected FCS files, along with the compensation matrix.</p> </li> </ol> <p>The <strong>MC_normalized dataset</strong> includes FCS files that have been sorted by barcode.</p> <p><strong>Please note</strong> that in the IMC dataset, the following mass channels are blank:</p> <ul> <li><strong>Tumor-ROI</strong>: 80Ar, 127I, 131Xe, 145Nd, 146Nd, 149Sm, 160Gd, 171Yb, 174Yb, 176Yb, 190Os</li> <li><strong>SLO-ROI</strong>: 80Ar, 127I, 131Xe, 145Nd, 146Nd, 149Sm, 160Gd, 176Yb, 190Os</li> </ul> <p>The names attached to the file names are IDs.</p>
Single-cell RNA-Seq and TCR-Seq analysis of PD-1+ CD8+ T-cells responding to anti-PD-1 and anti-PD-1/CTLA-4 immunotherapy in melanoma
<p><strong>This dataset details the scRNASeq and TCR-Seq analysis of sorted PD-1+ CD8+ T cells from patients with melanoma treated with checkpoint therapy (anti-PD-1 monotherapy and anti-PD-1 & anti-CTLA-4 combination therapy) at baseline and after the first cycle of therapy. A major publication using this dataset is accessible here: (reference) </strong></p> <p> </p> <p><strong>*experimental design</strong></p> <p> Single-cell RNA sequencing was performed using 10x Genomics with feature barcoding technology to multiplex cell samples from different patients undergoing mono or dual therapy so that they can be loaded on one well to reduce costs and minimize technical variability. Hashtag oligomers (oligos) were obtained as purified and already oligo-conjugated in TotalSeq-C format from BioLegend. Cells were thawed, counted and 20 million cells per patient and time point were used for staining. Cells were stained with barcoded antibodies together with a staining solution containing antibodies against CD3, CD4, CD8, PD-1/IgG4 and fixable viability dye (eBioscience) prior to FACS sorting. Barcoded antibody concentrations used were 0.5 µg per million cells, as recommended by the manufacturer (BioLegend) for flow cytometry applications. After staining, cells were washed twice in PBS containing 2% BSA and 0.01% Tween 20, followed by centrifugation (300 xg 5 min at 4 °C) and supernatant exchange. After the final wash, cells were resuspended in PBS and filtered through 40 µm cell strainers and proceeded for sorting. Sorted cells were counted and approximately 75,000 cells were processed through 10x Genomics single-cell V(D)J workflow according to the manufacturer’s instructions. Gene expression, hashing and TCR libraries were pooled to desired quantities to obtain the sequencing depths of 15,000 reads per cell for gene expression libraries and 5,000 reads per cell for hashing and TCR libraries. Libraries were sequenced on a NovaSeq 6000 flow cell in a 2X100 paired-end format.</p> <p> </p> <p><strong>*extract protocol</strong></p> <p> PBMCs were thawed, counted and 20 million cells per patient and time point were used for staining. Cells were stained with barcoded antibodies together with a staining solution containing antibodies against CD3, CD4, CD8, PD-1/IgG4 and fixable viability dye (eBioscience) prior to FACS sorting. Barcoded antibody concentrations used were 0.5 µg per million cells, as recommended by the manufacturer (BioLegend) for flow cytometry applications. After staining, cells were washed twice in PBS containing 2% BSA and 0.01% Tween 20, followed by centrifugation (300 xg 5 min at 4 °C) and supernatant exchange. After the final wash, cells were resuspended in PBS and filtered through 40 µm cell strainers and proceeded for sorting. Sorted cells were counted and approximately 75,000 cells were processed through 10x Genomics single-cell V(D)J workflow according to the manufacturer’s instructions.</p> <p> </p> <p><strong>*library construction protocol</strong></p> <p> Sorted cells were counted and approximately 75,000 cells were processed through 10x Genomics single-cell V(D)J workflow according to the manufacturer’s instructions. Gene expression, hashing and TCR libraries were pooled to desired quantities to obtain the sequencing depths of 15,000 reads per cell for gene expression libraries and 5,000 reads per cell for hashing and TCR libraries. Libraries were sequenced on a NovaSeq 6000 flow cell in a 2X100 paired-end format.</p> <p> </p> <p><strong>*library strategy</strong></p> <p> scRNA-seq and scTCR-seq</p> <p> </p> <p><strong>*data processing step</strong></p> <p> Pre-processing of sequencing results to generate count matrices (gene expression and HTO barcode counts) was performed using the 10x genomics Cell Ranger pipeline.</p> <p> Further processing was done with Seurat (cell and gene filtering, hashtag identification, clustering, differential gene expression analysis based on gene expression).</p> <p> </p> <p> <strong>*genome build/assembly</strong></p> <p> Alignment was performed using prebuilt Cell Ranger human reference GRCh38.</p> <p> </p> <p><strong>*processed data files format and content</strong></p> <p> RNA counts and HTO counts are in sparse matrix format and TCR clonotypes are in csv format.</p> <p>Datasets were merged and analyzed by Seurat and the analyzed objects are in rds format.</p> <p> </p> <table> <tbody> <tr> <td> <p><strong>file name</strong></p> </td> <td> <p><strong>file checksum</strong></p> </td> </tr> <tr> <td> <p>PD1CD8_160421_filtered_feature_bc_matrix.zip</p> </td> <td> <p>da2e006d2b39485fd8cf8701742c6d77</p> </td> </tr> <tr> <td> <p>PD1CD8_190421_filtered_feature_bc_matrix.zip</p> </td> <td> <p>e125fc5031899bba71e1171888d78205</p> </td> </tr> <tr> <td> <p>PD1CD8_160421_filtered_contig_annotations.csv</p> </td> <td> <p>927241805d507204fbe9ef7045d0ccf4</p> </td> </tr> <tr> <td> <p>PD1CD8_190421_filtered_contig_annotations.csv</p> </td> <td> <p>8ca544d27f06e66592b567d3ab86551e</p> </td> </tr> </tbody> </table> <p> </p> <table> <tbody> <tr> <td> <p><strong>*processed data file </strong></p> </td> <td> <p><strong>antibodies/tags</strong></p> </td> </tr> <tr> <td> <p>PD1CD8_160421_filtered_feature_bc_matrix.zip</p> </td> <td> <p>none</p> </td> </tr> <tr> <td> <p>PD1CD8_160421_filtered_feature_bc_matrix.zip</p> </td> <td> <p>TotalSeq™-C0251 anti-human Hashtag 1 Antibody - (HASH_1) - M1_base_monotherapy<br>TotalSeq™-C0252 anti-human Hashtag 2 Antibody - (HASH_2) - M1_post_monotherapy<br>TotalSeq™-C0253 anti-human Hashtag 3 Antibody - (HASH_3) - C1_base_combined_therapy<br>TotalSeq™-C0254 anti-human Hashtag 4 Antibody - (HASH_4) - C1_post_combined_therapy<br>TotalSeq™-C0255 anti-human Hashtag 5 Antibody - (HASH_5) - C2_base_combined_therapy<br>TotalSeq™-C0256 anti-human Hashtag 6 Antibody - (HASH_6) - C2_post_combined_therapy</p> </td> </tr> <tr> <td> <p>PD1CD8_160421_filtered_contig_annotations.csv</p> </td> <td> <p>none</p> </td> </tr> <tr> <td> <p>PD1CD8_190421_filtered_feature_bc_matrix.zip</p> </td> <td> <p>none</p> </td> </tr> <tr> <td> <p>PD1CD8_190421_filtered_feature_bc_matrix.zip</p> </td> <td> <p>TotalSeq™-C0251 anti-human Hashtag 1 Antibody - (HASH_1) - M2_base_monotherapy<br>TotalSeq™-C0252 anti-human Hashtag 2 Antibody - (HASH_2) - M2_post_monotherapy<br>TotalSeq™-C0253 anti-human Hashtag 3 Antibody - (HASH_3) - M3_base_monotherapy<br>TotalSeq™-C0254 anti-human Hashtag 4 Antibody - (HASH_4) - M3_post_monotherapy<br>TotalSeq™-C0255 anti-human Hashtag 5 Antibody - (HASH_5) - C3_base_combined_therapy<br>TotalSeq™-C0256 anti-human Hashtag 6 Antibody - (HASH_6) - C3_post_combined_therapy</p> </td> </tr> <tr> <td> <p>PD1CD8_190421_filtered_contig_annotations.csv</p> </td> <td> <p>none</p> </td> </tr> </tbody> </table> <p> </p>
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
ClinicalTrials.gov study NCT03308942. IPD Sharing: YES. Countries: 1. Publications: 1.
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
ClinicalTrials.gov study NCT03111732. IPD Sharing: NO. Countries: 1. Publications: 4.
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT02298946. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
ClinicalTrials.gov study NCT04902040. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
ClinicalTrials.gov study NCT03085719. IPD Sharing: NO. Countries: 1. Publications: 0.
Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
ClinicalTrials.gov study NCT04649476. IPD Sharing: NO. Countries: 1. Publications: 2.
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
ClinicalTrials.gov study NCT01096602. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
ClinicalTrials.gov study NCT03274804. IPD Sharing: NO. Countries: 1. Publications: 1.
PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
ClinicalTrials.gov study NCT03155425. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
ClinicalTrials.gov study NCT04165772. IPD Sharing: YES. Countries: 1. Publications: 4.
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
ClinicalTrials.gov study NCT04340882. IPD Sharing: NO. Countries: 1. Publications: 1.
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive
ClinicalTrials.gov study NCT02852655. IPD Sharing: NO. Countries: 1. Publications: 1.
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
ClinicalTrials.gov study NCT05275023. IPD Sharing: YES. Countries: 8. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.